[ad_1]
Pfizer is getting out of the enterprise of growing and advertising HIV medicines by exiting its minority stake in ViiV Healthcare, an organization the pharmaceutical big shaped in partnership with GSK 17 years in the past.
Below a brand new settlement, Pfizer’s possession in ViiV can be changed by Shionogi, one other minority shareholder of the HIV firm. In keeping with deal phrases introduced Tuesday, ViiV is canceling Pfizer’s 11.7% stake within the firm and Pfizer will obtain $1.875 billion. In the meantime, ViiV will subject new shares to Shionogi for $2.125 billion, boosting the Japanese firm’s stake in ViiV to from 10% to 21.7%.
GSK, which has been ViiV’s majority shareholder because the firm’s inception, will keep a 78.3% stake. The London-based pharma firm will even obtain a particular dividend of $250 million, payable in British kilos. The transaction nonetheless requires regulatory clearances in sure markets, however is predicted to shut within the present quarter.
ViiV launched in 2009 with a portfolio of 10 HIV medicines from GSK and Pfizer together with plans for the event of recent medicine stemming from the analysis of each firms. On the time, GSK owned 85% of ViiV and Pfizer owned 15%. In 2012, ViiV acquired international rights to HIV medicine developed in collaboration with Shionogi. In return, Shionogi grew to become a ten% shareholder in ViiV and gained a seat on the corporate’s board of administrators.
The ViiV portfolio presently has 15 authorized medicines whose income is recorded by GSK. In 2024, GSK reported HIV medicines generated £7.1 billion (about $9.5 billion) in gross sales, a ten.9% enhance in comparison with the prior yr. The highest ViiV product is Dovato, a once-daily capsule authorized for treating HIV in sufferers age 12 and older. GSK reported £2.2 billion (about $2.9 billion) in 2024 income for Dovato.
Pfizer’s monetary experiences had acknowledged dividends from ViiV as revenue. Within the context of HIV drug gross sales, these funds are nominal. For 2024, Pfizer reported a $272 million dividend from ViiV; within the prior yr, the dividend was $265 million.
ViiV’s fundamental rival in HIV medicines is Gilead Sciences. The most recent product in Gilead’s HIV portfolio is Yeztugo, a twice-yearly injection that final summer season received FDA approval for HIV-1 pre-exposure prophylaxis (PrEP). ViiV’s FDA-approved PrEP drug Apretude is run as an injection each different month, however the firm has been testing an ultra-long-acting model of the drug that would allow dosing intervals of 4 to 6 months. That work, together with a ViiV pipeline of 4 preclinical HIV medicines, will now proceed with simply two companions.
“This settlement simplifies ViiV’s shareholder construction and we look ahead to persevering with our extremely profitable collaboration with Shionogi to advance ViiV’s pipeline and portfolio of long-acting injectable HIV remedy and prevention medicines,” David Redfern, chair of ViiV Healthcare, stated in a ready assertion.
Picture by Flickr person NIAID through a Artistic Commons license
[ad_2]
